Core Viewpoint - A class action has been filed against Beyond Meat, Inc. for allegedly making false and misleading statements to investors regarding the valuation of its long-lived assets and the potential for a material impairment charge [1][2]. Group 1: Allegations and Financial Impact - The complaint alleges that Beyond Meat failed to disclose that the book value of certain long-lived assets exceeded their fair value, which could lead to a significant non-cash impairment charge [2]. - On October 24, 2025, Beyond Meat announced it expected to record a material non-cash impairment charge for the third quarter of 2025, resulting in a stock price drop of over 23% [3]. - The financial results released on November 10, 2025, indicated a loss from operations of $112.3 million for the third quarter, which included $77.4 million in non-cash impairment charges, causing the share price to fall nearly 9% [3]. Group 2: Class Action Participation - Shareholders interested in serving as lead plaintiffs must submit their papers by March 24, 2026, but participation is not required to be eligible for recovery [4]. - The law firm Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses [5].

New York, New York--(Newsfile Corp. - January 27, 2026) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Fermi Inc. (NASDAQ: FRMI), certain of the Company's senior executives and directors, and underwriters of Fermi's Initial Public Offering after a significant stock drop resulting from potential violations of the federal securities laws. If you invested in Fermi, you are encouraged to obtain additional information by visiting: https://ww ...

Core Points - A class action lawsuit has been filed against CoreWeave, Inc. and certain senior executives for securities fraud following significant stock drops due to potential violations of federal securities laws [1][3] - Investors are encouraged to seek additional information regarding the lawsuit and their legal options [2][9] Company Overview - CoreWeave is an AI-focused cloud computing company that operates data centers providing high-performance GPU infrastructure, relying on partners like Core Scientific for development [4] - The company had announced a merger agreement with Core Scientific on July 7, 2025 [4] Allegations and Stock Performance - CoreWeave allegedly overstated its ability to meet customer demand and concealed significant construction delays at its data centers, despite assuring investors of its competitive strengths [5] - The stock price dropped significantly due to various announcements: - On October 30, 2025, the stock fell by $8.87 (over 6%) after Core Scientific failed to secure enough shareholder votes for the merger, dropping from $139.93 to $131.06 [6] - On November 10, 2025, the company lowered its guidance for revenue and other metrics, leading to a drop of $17.22 (over 16%) from $105.61 to $88.39 [7] - On December 15, 2025, reports of delays in a major data center project caused the stock to drop by $2.85 (over 3%) from $72.35 to $69.50 [8]

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving BigBear.ai Holdings, Inc. and its officers or directors [1] Group 1: Company Performance - Cantor analysts downgraded BigBear from Overweight to Neutral on January 7, 2026, citing a 20% year-over-year revenue decline [3] - The downgrade was attributed to elevated execution risk due to reliance on inconsistent government contracts, leading to ongoing operating losses and margin pressure [3] - BigBear reported an adjusted EBITDA of ($9.4 million) in Q3 2025 and an operating margin of (66.0%) [3] Group 2: Market Reaction - Following the downgrade by Cantor, BigBear's stock price decreased by $0.42 per share, or 6.55%, closing at $5.99 per share on January 7, 2026 [3]

Core Viewpoint - Pomerantz Law Firm is investigating potential securities fraud or unlawful business practices involving Apogee Enterprises and its officers or directors [2]. Financial Performance - On January 7, 2025, Apogee reported third-quarter financial results for the 2026 fiscal year, with sales of $355.3 million, which fell short of the consensus estimate of $348.6 million [4]. - The CEO attributed the disappointing results to "higher aluminum, restructuring and health insurance costs" [4]. - Following the announcement, Apogee's stock price dropped by $5.18 per share, or 13.89%, closing at $32.11 per share on January 7, 2026 [4]. Legal Investigation - The investigation by Pomerantz LLP is focused on claims related to securities fraud or other unlawful business practices by Apogee and its management [2]. - Investors are encouraged to contact Pomerantz LLP for more information regarding the class action [3]. Firm Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of over 85 years in fighting for victims of securities fraud and corporate misconduct [5]. - The firm has successfully recovered numerous multimillion-dollar damages awards for class members [5].

Core Viewpoint - Pomerantz Law Firm is investigating claims on behalf of investors of AST SpaceMobile, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [2]. Group 1: Investigation Details - The investigation focuses on whether AST and certain officers and/or directors have engaged in securities fraud or other unlawful business practices [2]. - Investors are encouraged to contact Pomerantz LLP for more information regarding the investigation [1]. Group 2: Market Reaction - On January 7, 2026, Scotiabank downgraded AST to Sell, citing significant competition from SpaceX's Starlink, slow customer adoption, and delays in launching AST's satellites [4]. - Following the downgrade, AST's stock price fell by $11.76 per share, or 12.06%, closing at $85.73 per share on the same day [4].

Core Viewpoint - Pomerantz Law Firm is investigating claims on behalf of investors of First Solar, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1][2]. Group 1: Company Performance and Analyst Ratings - On January 7, 2026, Jefferies downgraded First Solar from Buy to Hold, citing lowered guidance, significant de-bookings, and margin compression throughout 2025 [4]. - Following this downgrade, First Solar's stock price decreased by $27.67 per share, or 10.29%, closing at $241.11 per share on the same day [4]. Group 2: Legal Investigation - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, and is currently investigating potential claims against First Solar [5].

NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  AppLovin Corporation (“AppLovin” or the “Company”) (NASDAQ: APP).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether AppLovin and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On Januar ...

NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  PDD Holdings Inc. (“PDD” or the “Company”) (NASDAQ: PDD).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether PDD and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On January 19, 2026, B ...

NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Beta Bionics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On ...